Ibiglustat

Catalog No. A21083

Ibiglustat (Venglustat), a potential therapy for PD Parkinson??s disease, SRT in Fabry??s and Gaucher??s, is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with ability to cross the blood-brain barrier.
Catalog Num A21083
M. Wt 389.49
Formula C20H24FN3O2S
Purity >98%
Storage at -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
CAS No. 1401090-53-6
Synonyms Venglustat; SAR402671, SAR 402671, SAR-402671; GZ402671, GZ 402671, GZ-402671
SMILES O=C(O[[email protected]@H]1CN2CCC1CC2)NC(C)(C3=CSC(C4=CC=C(F)C=C4)=N3)C
Ibiglustat (Venglustat), a potential therapy for PD Parkinson??s disease, SRT in Fabry??s and Gaucher??s, is a selective, allosteric inhibitor of glucosylceramide synthase (GCS) with ability to cross the blood-brain barrier.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 25.67 mL 128.37 mL 256.75 mL
0.5 mM 5.13 mL 25.67 mL 51.35 mL
1 mM 2.57 mL 12.84 mL 25.67 mL
5 mM 0.51 mL 2.57 mL 5.13 mL

*The above data is based on the productmolecular weight 389.49. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.